Effects of the Selective α1A‐Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double‐Blind, Placebo‐ and Moxifloxacin‐Controlled Study

In order to determine the effects of therapeutic and supratherapeutic doses of silodosin on QT interval, healthy men (N = 186; aged 18–45 years) were randomized to receive silodosin (8 or 24 mg) or placebo for 5 days or moxifloxacin 400 mg (positive control, known to prolong QT) once on day 5. At baseline and on day 5, five ECGs were recorded 0.25 h before dosing and 1, 1.5, 2, 3, 4, 6, 8, 10, and 23.5 h after dosing. Adjusted mean differences (analysis of covariance) between silodosin and placebo in the change in individual heart rate–corrected QTc (QTcI) from baseline to day 5 were